The PDF was saved in your download folder or opened in a new tab in your browser. You can find the download folder on your drive or in the browser bar of Firefox and Safari at the top right next to the arrow icon.
At the end of 2017, the MLL partners decided to establish a Management Board as a collaborative entity to design and implement the company’s short and long-term strategic objectives. The purview of the Management Board includes strategic decisions on MLL’s development and its imminent internationalization.
Prof. Dr. Claudia Haferlach was Head of the Cytogenetics and Fluorescence In-situ Hybridization Department at the Laboratory for Special Leukemia Diagnostics, Clinic Munich-Großhadern, is cofounder of MLL and since 2005 has been Head of the Cytogenetics and Fluorescence In-situ Hybridization Department at MLL.
Before cofounding MLL in 2005, Prof. Dr. Dr. Haferlach was a senior physician at various large university clinics with habilitation in internal medicine and a specialization in hematology and internal oncology
Prof. Dr. Kern was in charge of immunophenotyping at the Laboratory for Special Leukemia Diagnostics, Clinic Munich-Großhadern, is cofounder of MLL and since 2005 has been Head of the Immunophenotyping Department at MLL.
At the heart of our work is the responsibility we accept for people suffering from leukemia in its various forms. Modern leukemia diagnosis demands a large and closely connected team of experienced physicians, biologists, bioinformatics specialists and medical technicians. Consistent sharing of test results between the various laboratory departments and the steady expansion of staff knowledge guarantee rapid and reliable diagnostics in each individual case. The team of excellently qualified staff members is therefore the nerve center at MLL.